Repligen was recognized as a critical supplier for COVID-19 vaccine development. The team at the Rancho Dominguez Center of Excellence played a vital role in the successful production of over 500 million COVID-19 vaccines for a major manufacturer. We are proud of the part we play in the effort to end the pandemic.
Repligen introduces novel affinity resin for the purification of the SARS CoV-2 Spike Protein for vaccine development and manufacturing. NGL COVID-19 Spike Protein Affinity Resin binds the SARS-CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step. The resin is available in off-the shelf, pre-packed and pre-qualified OPUS® Columns for rapid implementation as well as in loose resin formats.
Rapid response with COVID-19 prioritized lead times
Proven technologies with broad customer base from clinical to commercial = reduced risk
Adoption in diverse platforms including mAbs, proteins, viruses, plasmids, AAV, Lentivirus, mRNA
Expert-guided priority support for rapid technology implementation
Leading technologies for upstream process intensification, downstream processing, process analytics - scalable from bench to production scale
Closed, single-use bioprocessing — single-use, Gamma-irradiated, fully integrated flow paths
Configurable, sterile assemblies
Reduced installation time
High capacity rPA affinity resin
at a fraction of the cost
Configurable, sterile assemblies
Reduced installation time
Needs and Challenges
Downstream solutions
Needs and Challenges
Upstream solutions
Downstream solutions
Needs and Challenges
Upstream solutions
Downstream solutions
Upstream solutions
Downstream solutions
OPUS® Columns with Purolite Protein A Resin
High capacity rPA affinity resin at a fraction of the cost
Spectrum® Hollow Fiber TFF Filters
Low shear TFF,
1400 configurations
Closed, Gamma-irradiated, no cleaning validation